Skip to main content
. 2020 Aug 14;10:1470. doi: 10.3389/fonc.2020.01470

Table 5.

5- and 10-year breast cancer–specific survival (BCSS).

Subtype 5-year BCSS 10-year BCSS
Luminal A-like 99.6% 97.9%
HER2 overexpression 92.4% 88.6%
Luminal B-like (HER2 negative) 95.7% 86.3%
TNBC 85.6% 83.9%
Luminal B-like (HER2 positive) 89.5% 80.6%
Whole cohort 95.8% 91.4%